Upstream processes were the focus of most early applications of continuous bioprocessing. That is now changing, with many biologic manufacturers evaluating downstream continuous processing and suppliers preparing their portfolios for the anticipated pivot...
After posting revenue growth of 39%, Repligen CEO suggests this was driven by filtration and chromatography franchises, particularly customers in gene therapy.
